ZA200004452B - Use of cabergoline in the treatment of restless legs syndrome. - Google Patents

Use of cabergoline in the treatment of restless legs syndrome.

Info

Publication number
ZA200004452B
ZA200004452B ZA200004452A ZA200004452A ZA200004452B ZA 200004452 B ZA200004452 B ZA 200004452B ZA 200004452 A ZA200004452 A ZA 200004452A ZA 200004452 A ZA200004452 A ZA 200004452A ZA 200004452 B ZA200004452 B ZA 200004452B
Authority
ZA
South Africa
Prior art keywords
cabergoline
treatment
restless legs
legs syndrome
syndrome
Prior art date
Application number
ZA200004452A
Other languages
English (en)
Inventor
Peter Schueler
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ZA200004452B publication Critical patent/ZA200004452B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200004452A 1998-03-27 2000-08-28 Use of cabergoline in the treatment of restless legs syndrome. ZA200004452B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7963998P 1998-03-27 1998-03-27

Publications (1)

Publication Number Publication Date
ZA200004452B true ZA200004452B (en) 2002-02-27

Family

ID=22151836

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200004452A ZA200004452B (en) 1998-03-27 2000-08-28 Use of cabergoline in the treatment of restless legs syndrome.

Country Status (23)

Country Link
US (1) US6114326A (cs)
EP (1) EP1066038B1 (cs)
JP (1) JP2002507562A (cs)
KR (1) KR100597517B1 (cs)
CN (1) CN1303286A (cs)
AT (1) ATE313326T1 (cs)
AU (1) AU747751B2 (cs)
BR (1) BR9908953A (cs)
CA (1) CA2320204A1 (cs)
CZ (1) CZ297284B6 (cs)
DE (1) DE69929041T2 (cs)
DK (1) DK1066038T3 (cs)
EA (1) EA002554B1 (cs)
ES (1) ES2255255T3 (cs)
HU (1) HUP0101954A3 (cs)
IL (1) IL138522A0 (cs)
NO (1) NO20004799L (cs)
NZ (1) NZ507176A (cs)
PL (1) PL343593A1 (cs)
SK (1) SK13312000A3 (cs)
TR (1) TR200002759T2 (cs)
WO (1) WO1999048484A2 (cs)
ZA (1) ZA200004452B (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
KR100417489B1 (ko) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 효능제／길항제 혼합물
US6477408B1 (en) * 2000-03-07 2002-11-05 Northwestern University Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
US6426713B1 (en) * 2000-07-05 2002-07-30 Cirrus Logic, Inc. Independent control of calibration registers in a multi channel A-D converter
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
ATE424205T1 (de) * 2001-03-30 2009-03-15 Toray Industries Mittel zur behandlung des syndroms der unruhigen beine
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20030134844A1 (en) * 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) * 2002-03-12 2003-09-18 Morgenlander Joel C. Method of treating restless leg syndrome
IL163990A0 (en) 2002-04-05 2005-12-18 Euro Celtique Sa Pharmaceutical preparation containing oxycodone and naloxone
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
ES2310258T5 (es) 2002-08-30 2012-05-31 Kyowa Hakko Kogyo Co., Ltd. Antagonistas de los receptores de adenosina A2A para tratar el síndrome de piernas inquietas o mioclono nocturno
BRPI0414481A (pt) 2003-09-17 2006-11-14 Xenoport Inc métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
CN101132772B (zh) * 2005-01-28 2012-05-09 欧洲凯尔特公司 耐醇剂型
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EA019879B1 (ru) * 2005-12-29 2014-07-30 Лексикон Фармасьютикалз, Инк. Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
WO2007117431A2 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
WO2008046149A1 (en) * 2006-10-17 2008-04-24 Biologic Health Solutions Pty Ltd Herbal compositions for the prevention or treatment of restless leg syndrome
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US7939665B2 (en) 2007-05-04 2011-05-10 Apotex Pharmachem Inc. Efficient process for the preparation of cabergoline and its intermediates
EP2083008A1 (en) * 2007-12-07 2009-07-29 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
CA2757411C (en) 2009-04-01 2017-06-27 Teofilo Cardoso De Vasconcelos Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
UA116567C2 (uk) 2013-07-23 2018-04-10 Євро-Селтік С.А. Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
WO2018129351A1 (en) 2017-01-05 2018-07-12 Shriram Raghunathan Restless leg syndrome or overactive nerve treatment
US11103691B2 (en) 2019-10-03 2021-08-31 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome
CA3153343A1 (en) 2019-10-03 2021-04-08 Jonathan David CHARLESWORTH Peripheral nerve stimulation for restless legs syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Also Published As

Publication number Publication date
NO20004799D0 (no) 2000-09-26
TR200002759T2 (tr) 2001-02-21
DE69929041D1 (de) 2006-01-26
KR20010052222A (ko) 2001-06-25
AU747751B2 (en) 2002-05-23
CA2320204A1 (en) 1999-09-30
SK13312000A3 (sk) 2001-05-10
AU3353199A (en) 1999-10-18
KR100597517B1 (ko) 2006-07-10
HUP0101954A3 (en) 2002-09-30
US6114326A (en) 2000-09-05
BR9908953A (pt) 2000-12-05
EP1066038A2 (en) 2001-01-10
EP1066038B1 (en) 2005-12-21
NZ507176A (en) 2003-09-26
EA200000994A1 (ru) 2001-02-26
IL138522A0 (en) 2001-10-31
PL343593A1 (en) 2001-08-27
CN1303286A (zh) 2001-07-11
WO1999048484A3 (en) 1999-11-25
ATE313326T1 (de) 2006-01-15
ES2255255T3 (es) 2006-06-16
JP2002507562A (ja) 2002-03-12
CZ20003419A3 (cs) 2002-01-16
WO1999048484A2 (en) 1999-09-30
EA002554B1 (ru) 2002-06-27
NO20004799L (no) 2000-10-11
HUP0101954A2 (hu) 2001-12-28
CZ297284B6 (cs) 2006-10-11
DK1066038T3 (da) 2006-04-24
DE69929041T2 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
PL343593A1 (en) Use of cabergoline in the treatment of restless legs syndrome
YU15299A (sh) Farmaceutski sastavi
MXPA03003912A (es) Tratamientos nuevos para el sindrome de piernas inquietas.
EP1112070A4 (en) NEW SUBSTITUTED TRIAZOLE COMPOUNDS
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
EP0904345A4 (en) DISINFECTING COMPOSITIONS AND METHOD FOR DISINFECTING SURFACES
PT755249E (pt) Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose
IL158867A0 (en) Ostepontin and agonists thereof in treatment and/or prevention of neurological diseases
HUP0103845A3 (en) Disinfecting composition and its use
AU1074902A (en) Kahalalide f
CA98963S (en) Leg for table
ZA98420B (en) Use of pramipexole in the treatment of restless legs syndrome.
EP0681787A3 (en) Use of an enzyme for the manufacture of an agent suitable for the treatment and / or prophylaxis of coccidiosis.
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
GB2323028B (en) Wheel and housing for table leg
SI1187612T1 (en) Use of riluzole for the treatment of multiple sclerosis
AU3922900A (en) Use of (valeriana) for the treatment of restless leg syndrome and related disorders
IL139144A0 (en) Mycobacterial inhibitors
GB2337692B (en) Ajustable leg table
BG104914A (en) Paroxetine maleate
GB9815354D0 (en) Article retainer pad and an arrangement therefor
GEP20074097B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
EP1000569A4 (en) CHAIR AND ITS TURNTABLE
MXPA01010449A (es) Composicion y metodo util para el tratamiento del colico.
PL108051U1 (en) Piece of furniture for seating